Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1991 Nov;32(6):364–372. doi: 10.1007/BF01741331

Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody

A Hekman 1,✉, A Honselaar 1, W M J Vuist 1, J J Sein 1, S Rodenhuis 1, W W ten Bokkel Huinink 1, R Somers 1, Ph Rümke 1, C J M Melief 1
PMCID: PMC11038497  PMID: 1706642

Abstract

Six patients with progressive B cell non-Hodgkin's lymphoma have been treated with an IgG2a mouse monoclonal antibody (mAb) against the B cell differentiation antigen CD19, with total doses varying from 225 mg to 1000 mg. Free mAb was detected in the serum after doses of 15–30 mg. After the mAb infusions the number of circulating tumour cells was temporarily reduced, but in some cases antibody-coated cells remained in the circulation for several days. mAb penetrated to extravascular tumour sites; in general higher doses were required to saturate cells in the lymph nodes than to sensitize tumour cells in the bone marrow. mAb doses of up to 250 mg were given i.v. over 4 h without major toxicity. One patient twice achieved a partial remission after two periods of mAb treatment with an 8-month interval; the second remission lasted for 9 months. One patient showed a minor response. None of the patients made antibodies against the mouse immunoglobulin. Serum immunoglobulin levels were followed as a measure of the function of the normal B cell compartment; no significant changes were seen up to 6 months after mAb treatment.

Key words: Immunotherapy, B cell lymphoma, Monoclonal antibodies

Footnotes

Supported by the Dutch Cancer Society (grant NKI 84-14)

References

  • 1.Berinstein N, Levy R. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2. J Immunol. 1987;139:971. [PubMed] [Google Scholar]
  • 2.Bertram JH, Gill PS, Levine AM, Boquiren D, Hoffman FM, Meyer P, Mitchell MS. Monoclonal antibody T 101 in T cell malignancies: a clinical, pharmacokinetic, and immunologic correlation. Blood. 1986;69:752. [PubMed] [Google Scholar]
  • 3.Brown SL, Miller RA, Homing SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood. 1989;73:651. [PubMed] [Google Scholar]
  • 4.De Rie MA, Zeijlemaker WP, Von dem Borne AEGKr. Inhibition by vinca alkaloids and colchicine of antigenic modulation induced by anti-CD19 monoclonal antibodies. Leukemia Res. 1988;12:135. doi: 10.1016/0145-2126(88)90073-2. [DOI] [PubMed] [Google Scholar]
  • 5.De Rie MA, Schumacher TNM, Van Schijndel GMW, Van Lier RAW, Miedema F. Regulatory role of CD19 molecules in B-cell activation and differentiation. Cell Immunol. 1989;118:368. doi: 10.1016/0008-8749(89)90385-7. [DOI] [PubMed] [Google Scholar]
  • 6.Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989;73:1431. [PubMed] [Google Scholar]
  • 7.Eisenthal A, Lafreniere R., Lefor AT, Rosenberg SA. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res. 1987;47:2771. [PubMed] [Google Scholar]
  • 8.Fokkens WJ, Vroom ThM, Rijntjes E, Mulder PGH. Fluctuation of the number of CD-1(T6)-positive dendritic cells, presumably Langerhans cells, in the nasal mucosa of patients with an isolated grass-pollen allergy before, during and after the grass-pollen season. J Allerg Clin Immunol. 1989;85:39. doi: 10.1016/0091-6749(89)90176-0. [DOI] [PubMed] [Google Scholar]
  • 9.Foon KA. Biological response modifiers: the new immunotherapy. Cancer Res. 1989;49:1621. [PubMed] [Google Scholar]
  • 10.Hale G, Clark MR, Marcus R, Winter G, Dyer MJS, Phillips JM, Riechmann L, Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1984;ii:139. doi: 10.1016/s0140-6736(88)90588-0. [DOI] [PubMed] [Google Scholar]
  • 11.Harris DT, Mastrangelo MJ. Serotherapy of cancer. Semin Oncol. 1989;16:180. [PubMed] [Google Scholar]
  • 12.Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA. 1986;83:7893. doi: 10.1073/pnas.83.20.7893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kawase I, Komuta K, Hara H, Inoue I, Hosoe S, Ikeda T, Shirasaka T, Yokota T, Tanio Y, Masuno T, Kishimoto S. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin-2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res. 1988;48:1173. [PubMed] [Google Scholar]
  • 14.Knapp W, Dörken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, Von dem Borne AEGKr, editors. Leucocyte typing IV, 4th international workshop and conference on human leucocyte differentiation antigens, Vienna 1989. Oxford: Oxford University Press; 1989. [Google Scholar]
  • 15.Lowder JN, Meeker TC, Levy R. Monoclonal antibody therapy of lymphoid malignancy. Cancer Surv. 1985;4:359. [PubMed] [Google Scholar]
  • 16.Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood. 1985;65:1349. [PubMed] [Google Scholar]
  • 17.Morgan AC, Sullivan W, Graves S, Woodhouse CS. Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2. Cancer Res. 1989;49:2773. [PubMed] [Google Scholar]
  • 18.Munn DH, Cheung N-KV. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res. 1987;47:6600. [PubMed] [Google Scholar]
  • 19.Ortaldo JR, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, Reisfeld R. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol. 1987;138:3566. [PubMed] [Google Scholar]
  • 20.Pezzutto A, Dörken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol. 1987;138:2793. [PubMed] [Google Scholar]
  • 21.Press OW, Appelbaum F, Ledbetter JA, Marin PJ, Zarlin J, Kidd P, Thomas ED. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584. [PubMed] [Google Scholar]
  • 22.Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSanted K, Porter B, Kidd P, Thomas ED, Bernstein ID. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989;7:1027. doi: 10.1200/JCO.1989.7.8.1027. [DOI] [PubMed] [Google Scholar]
  • 23.Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B cell malignancies. Cancer Res. 1989;49:4906. [PubMed] [Google Scholar]
  • 24.Rankin EM, Hekman A. Mouse monoclonal antibodies against the idiotype of human B cell non-Hodgkin lymphomas: production, characterization and use to monitor the progress of disease. Eur J Immunol. 1984;14:1119. doi: 10.1002/eji.1830141211. [DOI] [PubMed] [Google Scholar]
  • 25.Rankin EM, Hekman A, Somers R, Ten Bokkel Huinink W. Treatment of two patients with B cell lymphoma with monoclonal anti-idiotype antibodies. Blood. 1985;65:1373. [PubMed] [Google Scholar]
  • 26.Shiloni E, Eisenthal A, Sachs D, Rosenberg SA. Antibody—dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol. 1987;138:1992. [PubMed] [Google Scholar]
  • 27.Slaper-Cortenbach ICM, Admiraal LG, Van Leeuwen EF, Kerr JM, Von dem Borne AEGKr, Tetteroo PAT. Effective purging of bone marrow by a combination of immunorosette depletion and complement lysis. Exp Hematol. 1990;18:49. [PubMed] [Google Scholar]
  • 28.Uckun FM, Ledbetter JA. Immunobiologic differences between normal and leukemic human B-cell precursors. Proc Natl Acad Sci USA. 1988;85:8603. doi: 10.1073/pnas.85.22.8603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Pecszalska K, Song CW, Wick MR, Myers DE, Waddick K, Ledbetter JA. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immuno-toxins. Blood. 1988;71:13. [PubMed] [Google Scholar]
  • 30.Vuist WMJ, Van Buitenen F, De Rie MA, Hekman A, Rümke P, Melief CJM. Potentiation by interleukin-2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xeno-transplantation model. Cancer Res. 1989;49:3783. [PubMed] [Google Scholar]
  • 31.WHO handbook for reporting results of cancer treatment. WHO Offset Publ. no 48, Geneva, WHO 1979
  • 32.Zola H. The surface antigens of human B lymphocytes. Immunol Today. 1987;8:308. doi: 10.1016/0167-5699(87)90018-1. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES